The Cheresh laboratory focuses on how microRNAs influence blood vessel growth in tumors and regulate the “angiogenic switch” enabling tumors to access a blood supply. The lab has also developed a new drug discovery platform that targets tumor-associated kinases by chemically locking them in the inactive state. To this end, a new drug is being developed that allosterically inhibits RAF kinase and has shown strong inhibitory activity against breast cancer, pancreatic cancer and brain cancer in preclinical cancer models. One near term goal of this research effort is to test this drug in patients with late stage cancer at the Moores Cancer Center.
« Previous | Next »
Back to top
DCP Home |
Contact DCP |
Viewing Files |
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®